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Approaches to the Formulation of
Standards for Carcinogenic Substances
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by N. Ya. Yanysheva,* Yu. G. Antomonov,*
R. E. Albert,t B. Altshuler,t and L. Friedmantt
After having agreed that standards are necessary for carcinogens that cannot be completely eliminated
from the environment, two exchange groups in the U.S.S.R.-U.S. Cooperative Program present their
different approaches to the problem. The Russian group has recommended a benzypyrene standard of0.1
,ug/l1003 of atmospheric air over populated regions and gives its experimental basis and theoretical
rationale in the rst part ofthisjoint paper. Lifetime experiments in adult rats over a wide range ofdose
levels permit the determination of a largest ineffective dose level with respect to theoretical time of first
tumor as well as incidence. The standard is set by extrapolation based on body weight and uses a safety
factor of 10 to account for the additional susceptibility in embryogenesis and childhood. The U. S. group
presents a mathematical model of time-to-tumor occurrence which permits the prediction of population
incidence and life span shortening from time-to-tumor data in animals or man. It assumes the distribution
of mortality-corrected time to tumor is lognormal with the nth power of time inversely proportional to
dose and with dose independence of the variability of the logarithm of time to tumor. The prediction is
made by combining this distribution, fitted to the data, with population mortality tables. Both groups
emphasize that substantial research efforts are necessary to improve the scientific basis for setting stan-
dards.
Introduction
This paper represents a joint contribution under
the auspices of the U.S.S.R.-U.S.A. Cooperative
Program in Environmental Health Research. They
summarize a series of discussions held at the Insti-
tute of General and Communal Hygiene in Kiev
during the summer of 1973 concerning the general
problem of formulating exposure standards for
chemical carcinogens. In the U.S.S.R., there is of-
ficial approval for an atmospheric exposure stan-
dard for benzpyrene in the occupational and general
environment. The standard was developed in the
U.S.S.R. after extended discussions and special re-
search. It was recognized the carcinogen standards
should be accepted as the legal basis for hygiene
practices despite the fact that many aspects of the
problem remain unsolved.In the U.S.A., the situa-
tion is complex. Exposure standards have evolved
over the past 30 years in the atomic energy field and
do have official sanction. Air quality criteria for
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particulates developed by the Environmental Pro-
tection Agency represent an indirect standard for
carcinogens, inasmuch as the particulates include
the polycyclic aromatic hydrocarbons. The Na-
tional Institute for Occupational Safety and Health
has been developing criteria documents for specific
substances which recommend exposure standards
for carcinogens such as asbestos and arsenic. The
Occupational Safety and Health Administration has
developed standards for the safe handling of car-
cinogens without reference to permissible limits of
exposure. The Delaney Clause of the Food, Drug
and Cosmetic Act prohibits the addition ofany car-
cinogens to food. Other regulations administered by
the Food and Drug Administration do imply con-
centration limits for certain carcinogenic contami-
nants such as aflatoxin and the residues of car-
cinogenic feed additives in cattle and poultry. Thus,
in the U.S.A., where there is considerable resis-
tance to the idea offormalizing exposure standards
for carcinogens, exposure standards are being used
in various ways. However, there is no clearly de-
fined or generally accepted methodology for de-
veloping such standards.
In view of the importance and diversity of ap-
proaches to this difficult problem, one aspect ofthe
81U.S.S.R.-U.S.A. Cooperative Program in En-
vironmental Health Research is concerned with
setting standards for carcinogens. The initial result
ofthis cooperative program is thisjoint publication.
The contribution from the U.S.S.R. is the work of
scientists who developed the experimental data on
benzpyrene carcinogenicity as well as the theoreti-
cal approach for applying this data to the formula-
tion ofbenzpyrene and other exposure standards in
air and water in the general and occupational envi-
ronments. The contribution from the U.S.A. is a
theoretical approach to the assessment of cancer
risks, which uses animal and epidemiological data
and characterizes risks both in terms of increased
cancer incidence and life span shortening.
The participating groups from both countries
agree that (1) standards are necessary for carcino-
gens that cannot be completely eliminated from the
environment and (2) that a substantial research ef-
fort is required to further the development of the
scientific basis for such standards.
Experimental Data for
Assessment of Hazards from
Small Doses of Carcinogens
At the present time, when no one has any doubts
about the necessity ofsetting permissible standards
for carcinogenic substances, acute importance at-
taches to the problems of a scientific basis and de-
velopment ofmethodological approaches for estab-
lishing admissible limits for these compounds in the
environment.
In view of the fact that up to now it is not clear
whether a threshold exists for the action of car-
cinogenic substances, a genuine problem for
hygiene is to determine the admissible doses ofcar-
cinogens, the specific action of which might show
up only beyond the human life span. This can be
attained by means of modeling, under the condi-
tions of an oncological experiment, ofthe quantita-
tive dependence of the action of the carcinogenic
agent, with subsequent extrapolation of the data to
the human organism. The basic stages of such a
process are the following: (1) the testing of various
carcinogen doses, ranging from the maximally ef-
fective to the minimally effective and maximally
noneffective doses, with animal observations
throughout life span; (2) mathematical modeling of
the relationships of carcinogen dose to tumorigenic
effect and of carcinogen dose to time of tumor oc-
currence; (3) the quantitative prediction of the car-
cinogen doses whose theoretical times offirst tumor
formation extend beyond the limits of the life span
in test animals; (4) extrapolation of the permissible
carcinogen dose from animal to man and the calcu-
lation of the maximal permissible concentration in
the environment.
The above will be illustrated using an example
associated with the establishment of the maximal
permissible concentration for benz(a)pyrene in the
atmosphere which has been adopted in the
U.S.S.R. Experimental study of the carcinogenic
activity of various benz(a)pyrene doses by intrat-
racheal administration served as the basis for this
standard. In addition to the controls, six
benz(a)pyrene treatment groups were tested with
total doses ranging from 0.005 to 25 mg. The car-
cinogen was administered in 10 monthly doses by
the method of Shabad (1). These tests made it pos-
sible to show the presence of a direct dose-effect
relationship. Lung tumors were observed in 80% of
the animals with the 25 mg carcinogen dose. Ofthe
affected animals, 42.5% had malignant tumors. As
the dose was reduced, the carcinogenic effect was
reduced correspondingly, as can be seen from Table
1. The minimal effective benz(a)pyrene dose was
0.1 mg. This dose induced only benign tumors in
14.4% of the animals. Doses of 0.02 and 0.005 mg
were inactive.
In addition to the dose-effect relationship, a pro-
nounced dose-time relationship was observed. For
example, in the case of the 25 mg benz(a)pyrene
Table 1. Occurrence of lung tumors in rats after ten intratracheal administrations of benz(a)pyrene at various total doses.
Animals Animals Time to Maximum
with with appearance life
Benz(a)pyrene tumors, malignant offirst span,
dose, mg Ssa tumors, %a tumor, months months
25.0 80.0 42.5 12 28
2.5 42.8 28.5 17 31
0.5 28.2 15.7 19 34
0.1 14.4 0 27 37
0.02 0 0 35
0.005 0 0 35
Controls 0 0 34
a Based on number of animals surviving 10 months.
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twelfth month after the initial exposure whereas in
the case of the animals that received the minimally
effective carcinogen dose (0.1 mg), the first tumor
was observed only after 808 days, i.e., when most
of the animals in the 25 mg dose group had died
from neoplasms.
The third relationship noted by us was the dose
dependence for the morphological structure oflung
neoplasms, namely, the predominance ofsquamous
carcinomas with large benz(a)pyrene doses and of
adenocarcinomas with small doses. The importance
of this observation lies in its agreement with the
data on the different ratios ofthe histological types
ofhuman lungcancer in regions withdifferent levels
of pollution (2, 3).
The maximal noneffective benz(a)pyrene dose
was determined on the basis of studies conducted
under experimental conditions, whereas under nat-
ural conditions, man is exposed to a variety ofcar-
cinogenic substances. This fact required additional
experiments involving the simultaneous introduc-
tion of benz(a)pyrene together with other sub-
stances into the lung (Table 2).
These combined exposure studies again showed
that 0.1 mg is the minimal effective benz(a)pyrene
dose, while 0.02 mg was the maximal noneffective
dose. However, it is necessary to note the limita-
tions of the experimental results, since the neo-
plasms were obtained on small groups of animals
and the benz(a)pyrene was administered intermit-
tently during only one-third ofthe total life span of
the animals (tenfold, once a month), while the
human organism is subjected to benz(a)pyrene ex-
Table 2. Occurrence of lung tumors in rats after intratracheal
administration of benz(a)pyrene with various solvents and
polycyclic aromatic hydrocarbons.
Mixture Benz(a)pyrene Tumor incidence,
instilled dose, mg %
Benz(a)pyrene 0.1 14.4
+ india ink 0.02 0
Control 0
Benz(a)pyrene 0.1 18.2
+ dust 0.02 0
Control 0
Benz(a)pyrene 0.1 26.3
+ Tween 60 0.02 0
Control 0
Benz(a)pyrene 0.1 14.2
+ dibenz(a,h)- 0.02 0
anthracene Control 0
Benz(a)pyrene 0.1 0
+ benz(g,h,i)perylene 0.02 0
+ pyrene Control 0
+ anthracene
+ chrysene
posure during the entire life span.
The experimental results provided the basis for
the mathematical modeling of the dose-response
relationships in terms of the following logarithmic
equation:
Y = 1Oln [(XnIX) +1]
where Y is the percentage of animals with tumors,
Xn is the carcinogen dose (mg), and X is the maxi-
mally noneffective dose (mg).
Based on the above model, the possible risk of
tumoroccurrence is predicted at the 6.9% level fora
benz(a)pyrene dose of 0.02 mg as can be observed
in Table 3.
Similar results were obtained in modeling the
dose-effect relationship with the aid of the expo-
nential function Y = 100 (1 - e-a). Under these
conditions, it is assumed that the carcinogenic ef-
fect cannot be greater than 100% orless than 0. This
model made it possible to estimate small
benz(a)pyrene risks in terms of an upper limit ob-
tained with the exponent (a = 1.555) determined by
the 0.1 mg point and a lower limit with the exponent
(a = 0.064) determined by the 25 mg point. As a
result, the risk oftumor occurrence was determined
for the 0.02 mg dose to have an upper limit of 3%
and a lower limit of 0.023%.
Since the above considerations imply that
benz(a)pyrene at doses which are noneffective in an
experiment could induce neoplasms under certain
conditions, we also used the dose-time relationship
as a more realistic basis for extrapolation.
The calculation for the time t offirst tumor occur-
rence with a small benz(a)pyrene dose d was done
by using the function t = (ald) + b, where a = 1.021
and b = 16.79. As shown in Table 4, the car-
Table 3. Calculated risk for lung tumor occurrence in rats after the
intratracheal introduction of various doses ofbenz(a)pyrene.
Benz(a)pyrene Animals with
dose, mg tumors, %
0.1 17.9
0.05 2.23
0.02 6.9
0.002 0.95
0.0005 0.24
Table 4. Calculated time t ofthe occurrence ofthe first lung tumor
following ten intratracheal administrations ofvarioustotal dosesof
benz(a)pyrene.
Benz(a)pyrene Time t,
dose, mg months
0.1 27.0
0.05 37.2
0.02 67.8
0.01 118.9
0.005 221.0
0.002 527.3
June 1979 83cinogenic effect from a 0.05 mg benz(a)pyrene dose
will manifest itself towards the 38th month, which
corresponds to the natural life span of the animals,
while the effects from a 0.02 mg dose (68th month)
and from a 0.01 mg dose (119th month) fall outside
the limits of the life span.
Consequently, for calculation of the maximum
permissible concentration of benz(a)pyrene in air,
we can take the 0.02 mg benz(a)pyrene dose and use
it in the formula for converting dose to concentra-
tion in air:
Cbenz(a)pyrene /100 m3 = 100 XPIBKV
where Cbenz(a)pyrene /100 m3 is the maximal permissi-
ble benz(a)pyrene concentration in 100 m3 ofair, X
is the maximal benz(a)pyrene dose for which the
calculated time of the first tumor extends beyond
the limits of maximal life span (0.02 mg). B is the
average weight ofthe experimental animal (0.3 kg);
P is the weight ofthe standard human (70 kg), K is a
safety factor (10), and V is the volume ofair inhaled
by a human during his lifetime (383, 250 m3).
As can be seen from the formula presented, we
make use ofa safety factor because all ofthe calcu-
lations were based on results obtained from adult
animals. The calculated concentration which is rec-
ommended as the benz(a)pyrene standard for the
atmospheric air of populated areas will affect chil-
dren who can be assumed to be much more sensi-
tive to the action of carcinogenic substances than
adults. In addition we must consider the possible
effect of carcinogens during embryogenesis.
Thus, considering the safety factor, the relation-
ship between human and experimental animal
weights and the volume of air used by a human
being during his lifetime, the average daily
maximum benz(a)pyrene concentration should not
exceed 0.1 ,ug/100 m3 of air.
In conclusion, it should be noted that the ap-
proach described above for deriving the maximal
permissible concentration forbenz(a)pyrene in air is
the first attempt to set a carcinogen standard in the
environment. There is no doubt that further investi-
gations are necessary to establish more accurately
the basis for extrapolation of animal data to man.
Use of the Temporal Aspects of
Tumor Formation for the
Estimation of Risks from
Exposure to Environmental
Carcinogens
The formulation ofexposure limits to carcinogens
in the environment is an important aspect of the
control of hazards from these toxic agents. Some
carcinogens can be eliminated from the environ-
ment without serious sacrifice. Other carcinogens
are associated with essential technological activities
where the complete elimination of environmental
contamination is impossible; here, it is necessary to
develop the methodology for estimating the levels
of risk according to level of exposure in order to
achieve a rational basis for selecting permissible
exposure standards. We have advocated the posi-
tion that in order to completely define the nature of
the hazards from a carcinogen, it is necessary not
only to define the increased risk of developing
cancer at any given level of exposure, but also the
age at which the extracancers would occurand thus
the amount of life-span which would be lost by the
individuals who would not otherwise have de-
veloped cancer in the absence of such extra car-
cinogen exposure (4).
In orderto define the age ofoccurrence ofcancer,
it is necessary to characterize carcinogenic re-
sponse on a temporal basis. This requires a mathe-
matical formulation which provides an accurate and
systematic description of the time ofcancer occur-
rence independent of the complications of extrane-
ous mortality. Such a mathematical formulation can
then be combined with population survival statistics
to obtain the desired response in terms of cancer
incidence and age of occurrence. Since human
population survival has not been accurately de-
scribed by a mathematical function, especially at
the very advanced ages, the interaction of survival
with the mathematical description of mortality-
corrected tumor response is necessarily done by
numerical computation.
A central issue is whether there is a mathematical
formulation that satisfactorily describes the time
pattern of cancer occurrence. A promising de-
velopment in this regard is a formulation first pro-
posed by Blum on the basis of the skin tumor re-
sponse of mice to ultraviolet radiation (5) and later
extended by Druckrey to a variety ofchemical car-
cinogens and target organs on rodents (6). We have
also shown that it is applicable to radiation cancerin
terms ofthe osteogenic sarcoma response in mice to
226Ra and in humans to cigarette smoking (4). This
formulation has two elements. The first is that at
any given dose level of a carcinogen, administered
for the lifetime ofthe exposed animals, the cumula-
tive mortality-corrected tumor incidence will have a
lognormal shape. In other words, the temporal pat-
tern of response can be described completely by
two parameters: the median or 50%o time of tumor
occurrence t and the geometric standard deviation
0q. The second element of this formulation is that
when a population of animals is subdivided into
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group is exposed to adifferent daily dose leveld ofa
carcinogen, the tumor responses of each treatment
group will differ only in the median time of tumor
occurrence t, with the value of o-, remaining un-
changed. This means that the higher dose not only
reduces the median time of tumor formation but
also causes the same proportionate decrease in the
time of tumor occurrence for all of the exposed
animals. Furthermore, the relationship oft and d is
expressed by the equation
dt" = constant
where d is daily dose, t is time to 50% cancer inci-
dence, and n is a constant exponent. When n = 1,
the median appearance time is proportional to the
reciprocal ofthe daily dose, e.g., doubling the dose
rate halves the median tumor appearance time.
When n has a high value, the median appearance
time oftumors is affected relatively little by changes
in dose rate.
Model calculations have been done to examine
the interacting effects of cr and n on the various
tumor response parameters, including tumor inci-
dence (the proportion ofresponders)p, age at tumor
occurrence r, and life-span loss of the individuals
developing cancer 8, and the life-span loss in the
population as a whole A. These calculations which
assumed dt" is constant and o, is constant and use
U. S. vital statistics tables with dose normalized so
that when dose is unity, median tumor time equals
the average lifetime, have been presented in detail
elsewhere and are useful to illustrate the general
patterns of response (4).
The value ofn determines the shape of the dose-
response curve for incidence. The curves for inci-
dence p and population life shortening A are S-
shaped and asymmetrical. For a higher value of n,
the early steplike increase, which is a quasi-
threshold, occurs at a lower dose rate, and the later
part ifflatter at the higher dose rate. The higher the
value ofn, the greater the impact oflow dose rates.
This result reflects the greater insensitivity of me-
dian time t to changes in dose rate with higher n.
These considerations suggest that a high value ofn
is unfavorable for a downward extrapolation ofdose
rate to achieve negligible effect levels.
At low incidence levels, where t is much greater
than the maximum life-span, the incidence p and
population life shortening, A are strongly dependent
on the magnitude of the geometric standard devia-
tion0-,. The value ofo- also influences the values of
8 and T; the larger the o-, the younger the average
age ofcancer occurrence r and the greater the indi-
vidual loss of life-span 8.
It is to be noted that, regardless of the value ofn
or cr, the dose-incidence curve is complex and does
not fit any ofthe conventionally assumed forms, as
for example, a linear or log-normal shape. This fol-
lows from the fact that the incidence curve includes
two components: a simple systematic behavior of
the mortality-independent temporal features of
tumor response, and the complex and empirically
determined survival pattern of the responding
populations. The latter is determined by a large
number offactors and the resultant incidence curve
is necessarily complicated.
It also needs to be emphasized that at the present
time, there are comparatively few experiments that
have determined the temporal features of tumor
formation. Hence, the analysis presented above
represents no more than a suggested direction for
further investigation of the general problem of de-
termining the dose-dependence of tumor response.
It is quite possible that no simple formulation will be
applicable to all the various types of tumorigenic
responses. Furthermore, the credibility of any for-
mulation will depend on developing an understand-
ing of the underlying mechanisms that determine
the time pattern of tumor occurrence.
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